[Pharm-policy] CIPLA prices for nevirapine

[James Love]

http://www.cipla.com/whatsnew/ciplanews.htm

This is a March 20  (2000?) press release from CIPLA regarding its
pricing of Nevirapine, a non-nucleoside reverse transcriptase inhibitor
(NNRTI).  The CIPLA product is called Nevimune.  The name is of the
Boehringer Ingelheim product is Viramune.

CIPLA says it took two years to develop the product, at a cost of Rs 5
core.  ($1.1 million in US currency).  

The announced pricing of Nevimune was 135 Rs per tablet, compared to Rs
344 per tablet for Viramune  (about $3 compared to $8 per tab).

The CIPLA price for a capsule of d4T was given at 30 Rs (30 mg) to 36.5
Rs (40 mg), or $.66 to $.80 in US currency.  This is quite a bit higher
than some estimates of the costs of manufacturing d4T.  The BMS price
for Zerit at drugstore.com is $4.15 to $4.30 per capsule.  Zerit is a
drug invented at Yale University on a US government grant.

The CIPLA price for AZT was given at 10 Rs (100 mg) to 25.5 Rs (300 mg)
per capsule, or $.22 to $.56 per capsule.  The Glaxo price for
Zidovudine at drugstore.com is $1.54 (100 mg) to $4.62 per tab.  AZT was
also developed by the NIH.  

CIPLA's press release notes that it is exporting the active ingredient
in Nevirapine to Latin America countries.  



-- 
=======================================================
James Love, Director           | http://www.cptech.org
Consumer Project on Technology | mailto:love@cptech.org 
P.O. Box 19367                 | voice: 1.202.387.8030
Washington, DC 20036           | fax:   1.202.234.5176
=======================================================